search
EmCell
THE WORLDS LARGEST CLINICAL EXPERIENCE IN EMBRYONIC STEM CELL TRANSPLANTATION FOR
VARIOUS DISEASES AND CONDITIONS.

Home
About EmCell
IMPORTANT MESSAGE
EmCell Therapy
Our Experience
List of diseases
Oncology
Diabetes Mellitus
Nervous system
Aging Problems
Immune Deficiency
Endoscopic Treatment of Liver Diseases
News
Experience of Application of Embryonic Stem Cells in Amyotrophic Lateral Sclerosis
Embryonic Stem Cells in New-Onset Type 2 Diabetes Mellitus
Embryonic Stem Cells in Pernicious Decompensated Type 2 Diabetes Mellitus
Embryonic Stem Cell Transplantation in Multiple Sclerosis
Embryonic Cell Suspensions in Rheumatoid Arthritis
Investment Projects
Clinical Trials
Publications
Patents
Mail center
Congresses and Conferences

16 YEARS OF INTERNATIONAL CLINICAL EXPERIENCE IN TRANSPLANTATION OF HUMAN EMBRYONIC/FETAL STEM CELLS. REVIEW.

Experience of Application of Embryonic Stem Cells in Amyotrophic Lateral Sclerosis

Experience of Application of Embryonic Stem Cells in Amyotrophic Lateral Sclerosis

Analyzed is the experience of 61 ALS patients (38 men and 23 women) who have been treated at the Cell Therapy Clinic since 1995, mean age 48,4±16,3. Duration of the disease before the initial treatment was as follows: up to 1 year – 10, up to 2 years – 18, up to 3 years – 29, over 3 years – 4. 

Indications for the treatment were confirmed ALS, progressive course, ineffectiveness of routine treatment; contraindications – stage III respiratory insufficiency, artificial ventilation, inability to swallow, G-tube. 

Course of treatment presupposed administration of 4 cell suspensions containing mesenchymal, ectodermal, and endodermal stem cells obtained from growth zones of 4-8 weeks old cadaverous embryos’ systems and organs; amounts administered varied from 0,5 to 4 ml, cell count - from 0,1 to 100x105/ml. 

During the first course of treatment, 67% of patients reported decreased weakness, improved appetite, decreased fasciculations, decreased spasticity, and higher spirits.  In the course of 2 months, 34% of patients observed increased range of motions in the extremities, decreased muscular rigidity, lower reflexes, decreased number of fasciculating muscle zones, better endurance of daily loads, less expressed dysphagia and dysarthria.   In 3-6 months, 58% of patients reported aggravation of condition and reversion of relevant symptoms.   II treatment was performed in 24 cases, in 12,8±4,3 months, III course – in 8 cases, in 10,6±3,9 months, IV course – in 3 cases, in 9,2±4,1 months. 

Repeated courses of treatment also allow for reduced weakness, fasciculations, spasticity, increased range of motions, improved speech and swallowing quality.

Conclusions:

  1. Embryonic stem cells don’t terminate degenerative process in motor neurons, but provide for palliation of ALS course. 
  2. The best results were achieved in the group where ALS duration didn’t exceed 1 year, and where neurological symptoms were not as markedly expressed as in patients at later stages.

 


Copyright © 1999-2008 EmCell.com     Create a WebsiteDeveloped by XTLabs, Inc.